Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | CETP | P11597 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | GALR1 | P47211 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146332 | 0.91 | GPR3 (0.44) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL19287491 | 0.89 | CETP (0.44) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL6764359 | 0.89 | KCNH2 (0.44) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL21487338 | 0.89 | KIF11 (0.44) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL14450778 | 0.89 | KIF11 (0.47) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL1526052 | 0.89 | NPC1 (0.53) | — | |
| SCHEMBL1526051 | 0.89 | GPR3 (0.42) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL2094855 | 0.87 | GPR3 (0.45) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL177506 | 0.87 | GPR3 (0.41) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL5670014 | 0.87 | CETP (0.54) | KIF11CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126619-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024046607-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023232967-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023232972-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023232959-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2022263519-A1 | ORGANIC ELECTRONIC DEVICE COMPRISING A COMPOUND OF FORMULA (I), DISPLAY DEVICE COMPRISING THE ORGANIC ELECTRONIC DEVICE AS WELL AS COMPOUNDS OF FORMULA (I) | NOVALED GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4106028-A1 | ORGANIC ELECTRONIC DEVICE COMPRISING A COMPOUND OF FORMULA (I), DISPLAY DEVICE COMPRISING THE ORGANIC ELECTRONIC DEVICE AS WELL AS COMPOUNDS OF FORMULA (I) | Novaled GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022209674-A1 | FLUOROPOLYETHER GROUP-CONTAINING SILANE COMPOUND | ダイキン工業株式会社 | 2022-10-06 | — | — | WO | disclosed |
| EP-1565430-B1 | BIGUANIDE DERIVATIVES | JACOBUS PHARMA CO INC (US) | 2010-02-17 | — | — | EP | disclosed |
| US-7563792-B2 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080176852-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7256218-B2 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1565430-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL CO. INC. (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040116428-A1 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004048320-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176852-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | QDPR, DHODH, GLMN | GPR3 2395/4885KIF11 4160/4885CETP 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.